Peri-Procedural Outcomes of Left Atrial Appendage Occlusion in Lower Versus Higher CHA2DS2-VASc Score
- PMID: 39894328
- DOI: 10.1016/j.amjcard.2025.01.033
Peri-Procedural Outcomes of Left Atrial Appendage Occlusion in Lower Versus Higher CHA2DS2-VASc Score
Abstract
Percutaneous left atrial appendage occlusion (LAAO) is used to prevent stroke in atrial fibrillation. We present a national registry analysis of peri‑procedural outcomes of LAAO among patients with lower versus higher CHA2DS2-VASc score. The National Readmissions Database was used to perform a retrospective review of all hospitalizations for percutaneous endocardial LAAO identified between September 2015 and November 2019. ICD codes for congestive heart failure, hypertension, type 2 diabetes, stroke, transient ischemic attack, thromboembolism, and vascular disease were identified. CHA2DS2-VASc was calculated. Lower CHA2DS2-VASc score was defined as <5 and higher score as ≥5. Propensity matched (PSM) analysis at index hospitalization and 30 days was used to compare a matched sample of patients undergoing LAAO with lower and higher CHA2DS2-VASc. Outcomes examined included all-cause mortality, stroke, major bleeding, pericardial effusion, and cardiac tamponade. A sample of patients who underwent LAAO with lower CHA2DS2-VASc (n = 40,879) and higher CHA2DS2-VASc (n = 14,438) was identified for crude analysis. From this cohort, a sample of patients with lower CHA2DS2-VASc (n = 14,219) and higher CHA2DS2-VASc (n = 14,388) was selected for PSM analysis. Both crude and PSM analyses at index hospitalization found higher odds of mortality in the higher CHA2DS2-VASc group but no significant difference in odds of major bleeding, stroke, pericardial effusion, or cardiac tamponade. Our findings showed associated a higher CHA2DS2-VASc score with a higher risk of mortality without an increased risk of common complications peri‑procedurally. In conclusion, findings display the overall safety of LAAO for patients with both lower and higher CHA2DS2-VASc score.
Keywords: CHA(2)DS(2)-VASc; atrial fibrillation; left atrial appendage occlusion; mortality; nationwide readmission database; pericardial effusion; stroke.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Steven J. Filby, MD reports a relationship with Boston Scientific Corporation that includes: consulting or advisory. Rafey Feroze, MD reports a relationship with Beckman Coulter Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous